Key Highlights

  • Net loss per share was USD 0.10 against an estimate of a USD 0.12 loss.
  • Net loss was USD 1.84 million, compared with USD 2.00 million.
  • Grant income was USD 1.29 million, compared with USD 1.23 million.
  • Cash and cash equivalents were USD 9.04 million at September 30, 2026.

Marker Therapeutics, Inc. (NASDAQ:MRKR) reported a third quarter 2026 net loss of USD 1.84 million, compared with USD 2.00 million a year earlier. Net loss per share was USD 0.10, compared with USD 0.12, against an estimate of a USD 0.12 loss.

The company is a clinical-stage immuno-oncology company developing T cell-based immunotherapies for hematological malignancies and solid tumors. It has not generated Revenue from sales or licensing of its product candidates, and its income comes from grants that fund research.

Third Quarter Results

Research and development expense was USD 2.17 million, compared with USD 2.35 million. General and administrative expense was USD 1.06 million, compared with USD 1.02 million, bringing total operating expenses to USD 3.23 million, compared with USD 3.37 million.

On the income side, grant income was USD 1.29 million, compared with USD 1.23 million, and interest income was USD 91,785, compared with USD 138,064. Weighted average shares outstanding were 19,314,742, compared with 16,757,678.

Nine-Month Results

For the nine months ended September 30, 2026, Research and Development expense was USD 6.49 million, compared with USD 9.66 million, and general and administrative expense was USD 3.43 million, compared with USD 3.34 million. The prior-year period also included a USD 453,135 loss on early termination of a vendor agreement. Total operating expenses were USD 9.92 million, compared with USD 13.45 million.

Grant income for the period was USD 2.73 million, compared with USD 2.44 million. Interest income was USD 337,231, compared with USD 428,578, and other income was USD 8,677, compared with USD 117,444.

The net loss was USD 6.85 million, compared with USD 10.46 million, and net loss per share was USD 0.35, compared with USD 0.75. Net cash used in Operating Activities was USD 7.62 million, compared with USD 10.11 million. The company had no financing cash flows in the period, compared with USD 9.86 million provided in the prior-year period, which included net proceeds from a common stock issuance.

Balance Sheet and Going Concern Disclosure

Cash and cash equivalents were USD 9.04 million at September 30, 2026, compared with USD 16.07 million at December 31, 2025. Restricted cash was USD 387,973, compared with USD 974,799, and deferred grant income was USD 387,973, compared with USD 974,799.

Total Assets were USD 12.50 million, compared with USD 19.07 million, and total liabilities were USD 2.00 million, compared with USD 2.27 million. Stockholders' Equity was USD 10.50 million, compared with USD 16.80 million, and the accumulated Deficit was USD 466.03 million. The cover page reports 16,673,127 common shares outstanding as of November 13, 2026.

The filing states that the company anticipates funding its operations into the second quarter of 2027, assuming no additional grant funds are received, and discloses substantial doubt about its ability to continue as a going concern. Management is considering raising additional Capital and intends to apply for further grants, which could extend funding beyond the fourth quarter of 2027, although the filing gives no assurance that capital or grants are obtained.

Q3 2026 in Summary: Key Takeaways From Marker Therapeutics

Marker Therapeutics closed the third quarter of 2026 with a net loss of USD 1.84 million, or USD 0.10 per share, compared with USD 2.00 million, or USD 0.12 per share, a year earlier. Grant income of USD 1.29 million was reported against operating expenses of USD 3.23 million.

The company ended the period with USD 9.04 million in cash and cash equivalents. The filing anticipates funding into the second quarter of 2027, assuming no additional grant funds, and carries a substantial doubt disclosure about its ability to continue as a going concern.